[go: up one dir, main page]

MX2022007955A - Regimenes de dosificacion de erdafitinib. - Google Patents

Regimenes de dosificacion de erdafitinib.

Info

Publication number
MX2022007955A
MX2022007955A MX2022007955A MX2022007955A MX2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A
Authority
MX
Mexico
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
MX2022007955A
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Jose Perez
Porre Peter Marie Z De
Anjali Narayan Avadhani
Yohann Loriot
Arlene O Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022007955(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022007955A publication Critical patent/MX2022007955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G01N33/575—
    • G01N33/57585—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)

Abstract

La presente invención proporciona un método para el tratamiento del cáncer con erdafitinib.
MX2022007955A 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib. MX2022007955A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20

Publications (1)

Publication Number Publication Date
MX2022007955A true MX2022007955A (es) 2022-07-27

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.

Country Status (26)

Country Link
US (2) US11077106B2 (es)
EP (2) EP3576740B1 (es)
JP (3) JP2020505425A (es)
KR (2) KR20250069693A (es)
CN (1) CN110198716A (es)
AU (2) AU2018216969B2 (es)
BR (1) BR112019016043A2 (es)
CA (1) CA3049737A1 (es)
DK (1) DK3576740T3 (es)
ES (1) ES2953005T3 (es)
FI (1) FI3576740T3 (es)
HR (1) HRP20230697T1 (es)
HU (1) HUE062453T2 (es)
IL (1) IL268463A (es)
JO (1) JOP20190190A1 (es)
LT (1) LT3576740T (es)
MX (2) MX2019009304A (es)
NZ (2) NZ796822A (es)
PH (1) PH12019501885A1 (es)
PL (1) PL3576740T3 (es)
RS (1) RS64778B1 (es)
SG (2) SG11201907199QA (es)
SI (1) SI3576740T1 (es)
SM (1) SMT202300233T1 (es)
TW (1) TWI874925B (es)
UA (1) UA126336C2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037920B1 (ru) 2014-09-26 2021-06-07 Янссен Фармацевтика Нв Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
WO2020165181A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
EP4548935A3 (en) * 2019-03-29 2025-08-06 JANSSEN Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP7747521B2 (ja) * 2019-03-29 2025-10-01 ヤンセン ファーマシューティカ エヌ．ベー． 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JOP20220182A1 (ar) * 2020-02-12 2023-01-30 Janssen Pharmaceutica Nv مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
TW202508591A (zh) * 2023-05-24 2025-03-01 比利時商健生藥品公司 癌症治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
LT3576740T (lt) 2023-08-10
ES2953005T3 (es) 2023-11-07
SI3576740T1 (sl) 2023-10-30
UA126336C2 (uk) 2022-09-21
MX2019009304A (es) 2019-09-19
TWI874925B (zh) 2025-03-01
JP2025024064A (ja) 2025-02-19
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
NZ796822A (en) 2025-12-19
SG10202105110VA (en) 2021-06-29
NZ755301A (en) 2025-12-19
BR112019016043A2 (pt) 2020-03-31
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
EP4286005A3 (en) 2024-03-06
AU2018216969A1 (en) 2019-07-25
HRP20230697T1 (hr) 2023-10-13
PH12019501885A1 (en) 2020-06-29
CA3049737A1 (en) 2018-08-09
US20220110935A1 (en) 2022-04-14
EP4286005A2 (en) 2023-12-06
KR20190110581A (ko) 2019-09-30
IL268463A (en) 2019-09-26
JP2020505425A (ja) 2020-02-20
SG11201907199QA (en) 2019-09-27
RS64778B1 (sr) 2023-11-30
US11077106B2 (en) 2021-08-03
AU2024201871A1 (en) 2024-04-11
PL3576740T3 (pl) 2023-09-11
JP2023022190A (ja) 2023-02-14
CN110198716A (zh) 2019-09-03
EP3576740A1 (en) 2019-12-11
EP3576740B1 (en) 2023-06-14
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
AU2018216969B2 (en) 2024-04-11
FI3576740T3 (fi) 2023-08-31
DK3576740T3 (da) 2023-07-24
US20200022976A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP3641770A4 (en) CANCER TREATMENT METHODS
PH12017501999A1 (en) K-ras modulators
EA201991818A1 (ru) Лечение рака
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
TW201613587A (en) Medical treatments based on anamorelin
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12017501864A1 (en) Compositions and methods for treating autism
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2018000694A (es) Tratamiento del prurito.
PH12021551949A1 (en) Cancer treatment
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
MX2017003728A (es) Sistema mejorador de sabor.
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro